On July 25, the Food and Drug Administration signed a contract to acquire “fresh” tissue from aborted babies so it could transplant that tissue into mice.
On Monday, the Trump administration canceled that contract.
This is an unambiguous victory for the sanctity of human life.
The underlying question now is: Will the federal government follow up on the cancelation of this one contract and completely and finally terminate its practice of spending approximately $100 million per year on research that creates a market for tissue taken from aborted babies?
This writer first reported about the FDA contract to acquire fetal tissue in an Aug. 7 story for CNSNews.com.
On June 13, the FDA had published a “presolicitation notice” of its intent to award the contract to a Bay Area nonprofit called Advanced Bioscience Resources.